Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulodexide for chronic heart failure
NL-OMON49874Phase 2Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2020
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in heart failure with reduced ejection fraction (HFrEF) comparing Sulodexide with Placebo (2 arms). Primary endpoint: Percent change of NT-proBNP from baseline to week 8. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
sulodexide
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NL-OMON49874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49874.